Skip to main content
S&P 5007,638.74+1.15%DOW51,825.11+0.71%NASDAQ26,396.33+1.61%BTC$76,697.00+1.20%ETH$2,460.03+2.21%GOLD$4,400.80+0.30%OIL$101.84-0.58%
Smart Investors Daily
MX

NASDAQ · MXCT

MaxCyte, Inc.

Healthcare · Medical - Devices

$1.18

Up+$0.03 (+2.54%)

Updated Sep 17, 2026, 6:31 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
170.68M
P/E ratio
-3.73
Dividend yield
0.00%
52-week range
$0.64 – $1.87
Volume
299.45K
Avg. volume
961.6K

Price performance

MXCT price history

1M range · 20 trading sessions · Daily adjusted prices

MXCT closed at $1.18 after 20 trading sessions, down 15.11% for the selected period.

Last close
$1.18
Period change
-15.11%
Period low
$1.16
Period high
$1.39
Daily close
View OHLC price history
MXCT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$1.20$1.23$1.1714$1.18299.45K
Sep 15, 2026$1.18$1.20$1.1709$1.19272.06K
Sep 14, 2026$1.19$1.19$1.13$1.175517.66K
Sep 11, 2026$1.20$1.21$1.16$1.16332.53K
Sep 10, 2026$1.22$1.23$1.18$1.19300.46K
Sep 9, 2026$1.29$1.29$1.22$1.22393.99K
Sep 8, 2026$1.29$1.29$1.25$1.275432.9K
Sep 4, 2026$1.25$1.30$1.25$1.28333.51K
Sep 3, 2026$1.27$1.27$1.22$1.26425.95K
Sep 2, 2026$1.24$1.305$1.22$1.27502.41K
Sep 1, 2026$1.26$1.28$1.215$1.24678.9K
Aug 31, 2026$1.19$1.315$1.19$1.29777.28K
Aug 28, 2026$1.30$1.30$1.21$1.22563.72K
Aug 27, 2026$1.31$1.325$1.28$1.28360.77K
Aug 26, 2026$1.35$1.35$1.31$1.31292.3K
Aug 25, 2026$1.38$1.39$1.34$1.35310.49K
Aug 24, 2026$1.36$1.40$1.35$1.39620.49K
Aug 21, 2026$1.40$1.40$1.355$1.38435.91K
Aug 20, 2026$1.39$1.405$1.36$1.38611.85K
Aug 19, 2026$1.29$1.40$1.2705$1.39948.46K

Latest MXCT news

The latest Smart Investors Daily articles mentioning MXCT.

Stock researchCompany · Overview

MXCT research

Overview

Company profile and research snapshot.

Company profile

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
MXCT recent ratings
DateFirmRatingTarget
Mar 25, 2026Craig-HallumBuy—
Aug 11, 2025BTIGNeutral—
Aug 7, 2025William BlairMarket Perform—
Mar 12, 2025StifelBuy—
Apr 23, 2024Stephens & Co.Overweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte’s common stock and a service-based restricte

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By